我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

普伐他汀对Ⅱ型糖尿病并发冠心病患者肱动脉内皮舒张功能的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2005年第4期
页码:
385-387
栏目:
临床研究
出版日期:
2005-09-05

文章信息/Info

Title:
Effects of Pravastatin on endotheliumdependent vasodilation in type 2 diabetes patients with coronary artery disease
作者:
黄飞雄; 邓兴臣; 吴晓亮
电白人民医院内二科，广东 茂名 525400
Author(s):
HUANG Feixiong;  DENG Xingchen ;  WU Xiaoliang
Department of Cardiology , Dian Bai People's Hospitol, Maoming , Guangdong 525400, China
关键词:
普伐他汀; 糖尿病; 冠状动脉疾病; 内皮
Keywords:
Pravastatin;  diabetes ;  coronary disease;  endothelium
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨普伐他汀对Ⅱ型糖尿病并发冠心病患者肱动脉内皮舒张功能的影响。方法 45例Ⅱ型糖尿病并发冠心病患者随机分为常规治疗组和普伐他汀治疗组，治疗4周前后均抽静脉血测定血脂，采用高分辨超声法检测治疗前后肱动脉内皮依赖性舒张功能（FMD）和非内皮依赖性舒张功能（NMD）。结果 普伐他汀治疗4周后肱动脉FMD（6.32±0.35）%较治疗前（2.50±0.21）%显著改善（P<0.05），而肱动脉NMD无显著性差异（P>0.05）。结论 短期口服普伐他汀（40 mg/d）对Ⅱ型糖尿病并发冠心病患者受损的血管内皮功能有改善作用。
Abstract:
AIM To investigate effects of Pravastatin on endotheliumdependent vasodilation in type Ⅱ diabetes patients with coronary artery disease. METHODS 45 subjects were randomly divided into the Pravastatin group and the control group. The concentrations of lipids were measured before and after 4 weeks of the treatment. In the meantime, flowmediated vasodilation and nitratemediated vasodilation were measured in the brachial artery by highresolution ultrasound technique. RESULTS Endotheliumdependent vasodilatin was improved after 4 weeks′ treatment with Pravasitatin (6.32±0.35)% compared with that before treatment (2.5±0.21)% and that in control treatment group(2.51±0.26)%(P<0.05). Howerer, nitratemediated vasodilation did not change significantly. CONCLUSION Endotheliumdependent vasodilation is impaired in type Ⅱ diabetes patients with coronary artery disease, which can be improved by 40 mg Pravastatin therapy in short period.

参考文献/References

［1］ Furchgott RF,Zawadaki JV.The obligatory of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine［J］ , Nature,1980,288:373-376.

［2］Treasure CB,Klein JL,Weinteraub WS,et al. Beneficial effects of cholesterollowering therapy on the coronary endothelium in patients with coronary artery disease［J］. N Engl J Med, 1995,332:481-487.

［3］Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus［J］. Diabetes Care,1997,20:1183-1197.

［4］Celermajer DS, Sorensen KE, Gooch VM, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis［J］ . Lancet,1992,340:1111-1115.

［5］ 刘月洁，吴艳君，李建国. 糖尿病内皮功能损伤的发生机制［J］.临床超声学杂志，2003，5：38-40.

［6］Ross R. Thepathoge nesis of atherosclerosis:a perspective for the 1990’s［J］. Nature,1993,362:801-809.

［7］Kaesemeyer WH, Caldwell RB, Huang JZ, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterollowering actions［J］. J Am Coll Cardiol,1999,33:234-241.

［8］Wassmann S, Faul A, Hennen B. Rapid effect of 3hydroxy3methylglutaryl coenzyme,a reductase inhibition, on coronary endothelial function［J］. Circ Res, 2003,93(9):98-103.

备注/Memo

备注/Memo:
收稿日期：2004-11-20.
更新日期/Last Update: 2010-01-05